Lixte Biotechnology announces first patient dosed in trial with NKI

LIXTE Biotechnology announced the dosing of the first patient in a new clinical trial in collaboration with the Netherlands Cancer Institute, NKI, and supported by F. Hoffmann-La Roche for treatment of unresponsive metastatic colorectal cancer. As part of the clinical trial, LIXTE is providing its lead compound, LB-100, and Roche is providing atezolizumab through the imCORE Network, a global academic-industry partnership that aims to accelerate cancer immunotherapy research through institution-sponsored studies.